The German Breast Group and Celgene Corporation

Release Summary

Long-Term GeparSepto Study Data Demonstrate Significantly Higher Disease-free Survival following ABRAXANE Therapy in Neoadjuvant Breast Cancer

The German Breast Group and Celgene Corporation